Epitopes

• 

  Subject Areas on Research

  • 1,10-Phenanthroline reversibility inhibits proliferation of two human prostate carcinoma cell lines (PC-3 and DU145). 
  • 60 kD Ro and nRNP A frequently initiate human lupus autoimmunity. 
  • 60-kDa Ro protein autoepitopes identified using recombinant polypeptides. 
  • A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing Antibodies. 
  • A MUC16 IgG Binding Activity Selects for a Restricted Subset of IgG Enriched for Certain Simian Immunodeficiency Virus Epitope Specificities. 
  • A Therapeutic Antibody for Cancer, Derived from Single Human B Cells. 
  • A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques. 
  • A Zika virus-specific IgM elicited in pregnancy exhibits ultrapotent neutralization. 
  • A cell-based multiplex immunoassay platform using fluorescent protein-barcoded reporter cell lines. 
  • A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. 
  • A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profiling. 
  • A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope. 
  • A highly conserved tyrosine residue in G protein-coupled receptors is required for agonist-mediated beta 2-adrenergic receptor sequestration. 
  • A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. 
  • A monoclonal antibody reactive with a second epitope of the 67,000-dalton human T cell antigen. 
  • A monoclonal antibody specific for the amino terminal sequence of human prorenin identifies a common epitope on renal and amniotic fluid inactive renins. 
  • A murine monoclonal antibody directed against the carboxyl-terminal domain of GRP78 suppresses melanoma growth in mice. 
  • A neutralizing epitope of the superantigen SEA has agonist activity on T cells. 
  • A new ganglioside of the lactotetraose series, GalNAc-3'-isoLM1, detected in human meconium. 
  • A novel antibody humanization method based on epitopes scanning and molecular dynamics simulation. 
  • A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design. 
  • A proposed nomenclature for the virion proteins of oncogenic RNA viruses. 
  • A rat liver 57-kDa protein is identified to share antigenic determinants with statin, a marker for nonproliferating cells. 
  • A self-assembling peptide acting as an immune adjuvant. 
  • A sensitive epitope-blocking ELISA for the detection of Chikungunya virus-specific antibodies in patients. 
  • A sequence-specific conformational epitope on U1 RNA is recognized by a unique autoantibody. 
  • A targeted and adjuvanted nanocarrier lowers the effective dose of liposomal amphotericin B and enhances adaptive immunity in murine cutaneous leishmaniasis. 
  • A tool for evaluating heterogeneity in avidity of polyclonal antibodies. 
  • Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens. 
  • Active immunotherapy for TNF-mediated inflammation using self-assembled peptide nanofibers. 
  • Affinity-purified antibody as a probe of RNA polymerase II subunit structure. 
  • Allogeneic microchimerism and donor antigen-specific hyporeactivity in lung transplant recipients. 
  • Alterations in slow-twitch muscle phenotype in transgenic mice overexpressing the Ca2+ buffering protein parvalbumin. 
  • Altered expression of ganglioside phenotypes of human gliomas in vivo and in vitro. 
  • Amplification of suppressor inducer pathway with monoclonal antibody, anti-2H4, identifying a novel epitope of the common leukocyte antigen/T200 antigen. 
  • An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1. 
  • An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. 
  • An MMP-degraded and cross-linked fragment of type III collagen as a non-invasive biomarker of hepatic fibrosis resolution. 
  • An altered immune response to Epstein-Barr nuclear antigen 1 in pediatric systemic lupus erythematosus. 
  • An antibody from single human VH-rearranging mouse neutralizes all SARS-CoV-2 variants through BA.5 by inhibiting membrane fusion. 
  • An antibody to human thymic Hassall's body epithelium recognizes a subset of blood group A antigens. 
  • An array of 60,000 antibodies for proteome-scale antibody generation and target discovery. 
  • Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. 
  • Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. 
  • Analysis of autoantibody binding to different regions of the human La antigen expressed in recombinant fusion proteins. 
  • Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. 
  • Analysis of recombinant Phex: an endopeptidase in search of a substrate. 
  • Anomalous MLR responsiveness among siblings. 
  • Anti-U1A monoclonal antibodies recognize unique epitope targets of U1A which are involved in the binding of U1 RNA. 
  • Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. 
  • Anti-idiotypic monoclonal Ig specific for an anti-laminin Ig heavy chain transgene variable region. 
  • Anti-receptor antibody-induced H-Y-specific delayed-type hypersensitivity responses in nonresponder mice. 
  • Anti-receptor antibody-induced suppression of murine H-Y-specific delayed-type hypersensitivity responses. 
  • Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. 
  • Antiadhesive properties of a quaternary structure-specific hybridoma antibody against type 1 fimbriae of Escherichia coli. 
  • Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds. 
  • Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. 
  • Antibodies to a Conserved Influenza Head Interface Epitope Protect by an IgG Subtype-Dependent Mechanism. 
  • Antibody Feedback Limits the Expansion of B Cell Responses to Malaria Vaccination but Drives Diversification of the Humoral Response. 
  • Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes. 
  • Antibody binding to a conformation-dependent epitope induces L-selectin association with the detergent-resistant cytoskeleton. 
  • Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates. 
  • Antibody responses to the HIV-1 envelope high mannose patch. 
  • Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses. 
  • Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. 
  • Antibody-selected mimics of hepatitis C virus hypervariable region 1 activate both primary and memory Th lymphocytes. 
  • Antigen-specific B cell detection reagents: use and quality control. 
  • Antigenic heterogeneity of human anaplastic gliomas and glioma-derived cell lines defined by monoclonal antibodies. 
  • Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. 
  • Antigenicity of a recombinant Ro (SS-A) fusion protein. 
  • Antigens from synthetic and natural estrogens: formation by conjugation with protein through a thiopropionic acid link. 
  • Antigens shared by rat schwannomas, neuroblastomas, and a testicular interstitial cell carcinoma. 
  • Applications of monoclonal antibodies in the diagnosis and treatment of primary brain tumors. 
  • Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas. 
  • Assembly and maturation of HLA-A and HLA-B antigens in vivo. 
  • Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope. 
  • Astrocyte cytolysis by MHC class II-specific mouse T cell clones. 
  • Augmentation of syngeneic tumor-specific immunity by semiallogeneic cell hybrids. 
  • Autoantibodies against cell surface GRP78 promote tumor growth in a murine model of melanoma. 
  • Autoantibodies specific for U1 RNA and initiator methionine tRNA. 
  • Autoimmune epitopes in messenger RNA. 
  • Autoimmunity to munc-18 in Rasmussen's encephalitis. 
  • Autoreactivity profiles of influenza hemagglutinin broadly neutralizing antibodies. 
  • Autoregulation of Tcr V region epitopes in autoimmune disease. 
  • B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. 
  • Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies. 
  • Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I. 
  • Binding of anti-GRP78 autoantibodies to cell surface GRP78 increases tissue factor procoagulant activity via the release of calcium from endoplasmic reticulum stores. 
  • Binding of factor VIII inhibitors to discrete regions of the factor VIII C2 domain disrupt phospholipid binding. 
  • Biophysical characteristics of anti-Gal(alpha)1-3Gal IgM binding to cell surfaces: implications for xenotransplantation. 
  • Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium. 
  • Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency. 
  • Brain adducin: a protein kinase C substrate that may mediate site-directed assembly at the spectrin-actin junction. 
  • Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models. 
  • Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. 
  • Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. 
  • C-terminal region of human T cell lymphotropic virus type I (HTLVI) p19 core protein is immunogenic in humans and contains an HTLVI-specific epitope. 
  • CD8 CTL responses in vaccines: emerging patterns of HLA restriction and epitope recognition. 
  • Carbohydrate Microarrays Identify Blood Group Precursor Cryptic Epitopes as Potential Immunological Targets of Breast Cancer. 
  • Cardiac xenografts between primate species provide evidence for the importance of the alpha-galactosyl determinant in hyperacute rejection. 
  • Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. 
  • Cellular immune response to cryptic epitopes during therapeutic gene transfer. 
  • Cellular immune response to viral peptides in patients exposed to HIV. 
  • Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. 
  • Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. 
  • Characterization of CD8(-) HLA class I/epitope tetrameric complexes binding T cells. 
  • Characterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop. 
  • Characterization of a monoclonal antibody that defines an immunoregulatory T cell subset for immunoglobulin synthesis in humans. 
  • Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies. 
  • Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity. 
  • Characterization of antigens in SSV nonproducer cells. 
  • Characterization of cytotoxic cells generated from in vitro cultures of murine bone marrow cells. 
  • Characterization of human chemotactic lymphokine production induced by mitogens and mixed leukocyte reactions using a new microassay. 
  • Characterization of the binding epitope of the monoclonal antibody DMAb-1 to ganglioside GM2. 
  • Cholera toxin B scaffolded, focused SIV V2 epitope elicits antibodies that influence the risk of SIVmac251 acquisition in macaques. 
  • Chromosome mapping of human cell surface molecules: monoclonal anti-human lymphocyte antibodies 4F2, A3D8, and A1G3 define antigens controlled by different regions of chromosome 11. 
  • Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation. 
  • Clinical applications of a peptide-based vaccine for glioblastoma. 
  • Clonal analysis of human anti-V3 monoclonal antibodies selected by a V3 tetramer. 
  • Cloning of mitogen- and antigen-reactive B lymphocytes on filter paper discs. I. A description of the technique and of methods for the analysis of colonies. 
  • Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes. 
  • Clustered charged amino acids of human adenosine deaminase comprise a functional epitope for binding the adenosine deaminase complexing protein CD26/dipeptidyl peptidase IV. 
  • Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. 
  • Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques. 
  • Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1. 
  • Common gamma chain cytokines promote rapid in vitro expansion of allo-specific human CD8+ suppressor T cells. 
  • Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers. 
  • Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs. 
  • Comparison of synovial fluid cartilage marker concentrations and chondral damage assessed arthroscopically in acute knee injury. 
  • Comparisons of mixed leukocyte reactions with skin graft survival in families genotyped for HL-A. 
  • Complement Factor H Antibodies from Lung Cancer Patients Induce Complement-Dependent Lysis of Tumor Cells, Suggesting a Novel Immunotherapeutic Strategy. 
  • Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. 
  • Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope. 
  • Computational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5. 
  • Conserved cryptic recombination signals in Vkappa gene segments are cleaved in small pre-B cells. 
  • Conserved epitope on influenza-virus hemagglutinin head defined by a vaccine-induced antibody. 
  • Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. 
  • Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein. 
  • Coordinator's report--section 2D3. 
  • Creation and properties of histocompatibility antigen-cell conjugates. I. Preparation and immunological properties of rat histocompatibility antigens. 
  • Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. 
  • Cross-Reactive Immunity Among Flaviviruses. 
  • Cross-desensitization of chemoattractant receptors occurs at multiple levels. Evidence for a role for inhibition of phospholipase C activity. 
  • Cross-reacting antigens on L5178Y cells which serve as targets for cytotoxic T-lymphocyte lysis during establishment of the tumor dormant state. 
  • Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. 
  • Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. 
  • Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens. 
  • Cross-reactive idiotypes in the sera of patients with bullous pemphigoid express anti-basement-membrane-zone activity. 
  • Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. 
  • Current status and strategies for vaccines against diseases induced by human T-cell lymphotropic retroviruses (HTLV-I, -II, -III). 
  • Cytogenetic engineering in vivo: restoration of biologic complement activity to C5-deficient mice by intravenous inoculation of hybrid cells. 
  • Deficient antibody-dependent cellular cytotoxicity against human immunodeficiency virus (HIV)-expressing target cells in perinatal HIV infection. 
  • Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. 
  • Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. 
  • Delineation of immunologically and biochemically distinct HLA-A2 antigens. 
  • Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. 
  • Dephosphorylation of distinct sites on microtubule-associated protein MAP1B by protein phosphatases 1, 2A and 2B. 
  • Description of monoclonal antibody defining an HLA allotypic determinant that includes specificities within the B5 cross-reacting group. 
  • Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheet. 
  • Design, expression, and immunogenicity of a soluble HIV trimeric envelope fragment adopting a prefusion gp41 configuration. 
  • Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease. 
  • Detection of both T-cell and Ia-like antigens on cells from patients with acute myelomonocytic leukemia and chronic myelogenous leukemia in blast crisis. 
  • Detection of glioma-associated gangliosides GM2, GD2, GD3, 3'-isoLM1 3',6'-isoLD1 in central nervous system tumors in vitro and in vivo using epitope-defined monoclonal antibodies. 
  • Determinants of Tenascin-C and HIV-1 envelope binding and neutralization. 
  • Determination of neutralization activities by a new versatile assay using an HIV-1 genome carrying the Gaussia luciferase gene. 
  • Development of Neutralization Breadth against Diverse HIV-1 by Increasing Ab-Ag Interface on V2. 
  • Development of a vaccine for the prevention of AIDS, a critical appraisal. 
  • Development of donor-specific and non-donor-specific HLA-DP antibodies post-transplant: the role of epitope sharing and epitope matching. 
  • Different adjuvanted pediatric HIV envelope vaccines induced distinct plasma antibody responses despite similar B cell receptor repertoires in infant rhesus macaques. 
  • Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate. 
  • Direct detection of cellular immune responses to cancer vaccines. 
  • Direct localization of monoclonal antibody-binding sites on Acanthamoeba myosin-II and inhibition of filament formation by antibodies that bind to specific sites on the myosin-II tail. 
  • Distinct CD4+ helper T cells involved in primary and secondary responses to infection. 
  • Distribution and physical properties of BCA200, a Mr 200,000 glycoprotein selectively associated with human breast cancer. 
  • Distribution of CD44 variant isoforms in human skin: differential expression in components of benign and malignant epithelia. 
  • Distribution of, and immune response to, chicken anti-alpha Gal immunoglobulin Y antibodies in wild-type and alpha Gal knockout mice. 
  • Drosophila TFIID binds to a conserved downstream basal promoter element that is present in many TATA-box-deficient promoters. 
  • Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. 
  • Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations. 
  • Effect of radioiodination on the binding of monoclonal antibody DF3 to breast carcinoma cells. 
  • Electron microscopic identification of exposed plasmin epitopes in alpha 2-macroglobulin-plasmin complex using monoclonal antibody-colloidal gold adducts. 
  • Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein. 
  • Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence. 
  • Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes. 
  • Engineering antibody-based molecules for HIV treatment and cure. 
  • Enhanced Th17-cell responses render CCR2-deficient mice more susceptible for autoimmune arthritis. 
  • Enhanced antibody responses to an HIV-1 membrane-proximal external region antigen in mice reconstituted with cultured lymphocytes. 
  • Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. 
  • Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma. 
  • Enthalpic signature of methonium desolvation revealed in a synthetic host-guest system based on cucurbit[7]uril. 
  • Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. 
  • Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. 
  • Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type IIA von Willebrand disease from those generated by plasmin. 
  • Epitope specificity of anti-La antibodies from patients with Sjögren's syndrome. 
  • Epitope tagging for tracking elastin-like polypeptides. 
  • Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. 
  • Epitope-specific signaling through CD45 on T lymphocytes leads to cAMP synthesis in monocytes after ICAM-1-dependent cellular interaction. 
  • Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. 
  • Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. 
  • Eplet mismatch scores and de novo donor-specific antibody development in simultaneous pancreas-kidney transplantation. 
  • Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model. 
  • Estimating the probability of polyreactive antibodies 4E10 and 2F5 disabling a gp41 trimer after T cell-HIV adhesion. 
  • Evidence for polyreactive xenoreactive antibodies in the repertoire of human anti-swine antibodies: the 'next' humoral barrier to xenotransplantation? 
  • Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. 
  • Evolutionarily conserved epitopes on human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus reverse transcriptases detected by HIV-1-infected subjects. 
  • Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. 
  • Exposure of an occluded hemagglutinin epitope drives selection of a class of cross-protective influenza antibodies. 
  • Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha1-3galactose. 
  • Expression and function of the gamma c subunit of the IL-2, IL-4, and IL-7 receptors. Distinct interaction of gamma c in the IL-4 receptor. 
  • Expression of a highly conserved anti-DNA idiotype in normal and autoimmune mice. 
  • Expression of cytokine mRNA in murine splenic dendritic cells and better induction of T cell-derived cytokines by dendritic cells than by macrophages during in vitro costimulation assay using specific antigens. 
  • Extracellular Loops of the Treponema pallidum FadL Orthologs TP0856 and TP0858 Elicit IgG Antibodies and IgG+-Specific B-Cells in the Rabbit Model of Experimental Syphilis. 
  • Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. 
  • Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines. 
  • Flavivirus serocomplex cross-reactive immunity is protective by activating heterologous memory CD4 T cells. 
  • Flow cytometry sorting of recombinant mycobacterial species yields bacterial clones with enhanced insert expression. 
  • Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. 
  • Frequent Development of Broadly Neutralizing Antibodies in Early Life in a Large Cohort of Children With Human Immunodeficiency Virus. 
  • Function and evolutionary conservation of distinct epitopes on the leukocyte adhesion molecule-1 (TQ-1, Leu-8) that regulate leukocyte migration. 
  • Functional, non-clonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region. 
  • Further characterization of erythrocyte p80 and the membrane protein defect of In(Lu) Lu(a-b-) erythrocytes. 
  • Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa. 
  • Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant. 
  • Genetic Identification of Two Novel Loci Associated with Steroid-Sensitive Nephrotic Syndrome. 
  • Genetic control of the immune response to staphylococcal nuclease. VIII. Mapping of genes for antibodies to different antigenic regions of nuclease. 
  • Genetic elimination of α3(IV) collagen fails to rescue anti-collagen B cells. 
  • Glioma-associated antigens defined by monoclonal antibodies against an avian sarcoma virus-induced rat astrocytoma. 
  • Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. 
  • Glucocorticoid receptor binding to rat liver nuclei occurs without nuclear transport. 
  • Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation. 
  • Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers. 
  • Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. 
  • Group-specific antigenic determinants of the large envelope glycoprotein of avian oncornaviruses. 
  • HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions. 
  • HIV antibodies and vaccine design. 
  • HIV envelope V3 region mimic embodies key features of a broadly neutralizing antibody lineage epitope. 
  • HIV immunization. Fresh pathways to follow. 
  • HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions. 
  • HIV vaccine development at Duke University Medical Center. 
  • HIV vaccines. Magic of the occult? 
  • HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques. 
  • HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. 
  • HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. 
  • HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. 
  • HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. 
  • HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. 
  • HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. 
  • HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence. 
  • HIV-1 intrapatient sequence diversity in the immunogenic V3 region. 
  • HIV-1 neutralization by chimeric CD4-CG10 polypeptides fused to human IgG1. 
  • HIV-1 neutralizing antibody and approaches to the envelope diversity problem. 
  • HIV-1 neutralizing monoclonal antibodies induced by a synthetic peptide. 
  • HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. 
  • HLA-A2 mutants immunoselected in vitro. Definition of residues contributing to an HLA-A2-specific serological determinant. 
  • HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. 
  • Heparin-induced decrease in circulating antithrombin-III. 
  • Heterogeneity in the phosphorylation of microtubule-associated protein MAP1B during rat brain development. 
  • Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. 
  • High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. 
  • High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. 
  • High-frequency alloreactive T cells augment effector function of low-frequency CD8+ T-cell responses under CD28/CD154 blockade. 
  • High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection. 
  • High-throughput affinity ranking of antibodies using surface plasmon resonance microarrays. 
  • Histocompatibility testing in chimpanzee families. 
  • Human B cell alloantigens: expression of MB and MT determinants. 
  • Human T cell antigen expression by primate T cells. 
  • Human T-cell leukemia/lymphoma virus: studies of host-virus interaction. 
  • Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. 
  • Human medullary thymocyte p80 antigen and In(Lu)-related p80 antigen reside on the same protein. 
  • Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain. 
  • Humans have antibodies capable of recognizing oncoviral glycoproteins: demonstration that these antibodies are formed in response to cellular modification of glycoproteins rather than as consequence of exposure to virus. 
  • Hybridoma SLE autoantibodies: insights for the pathogenesis of autoimmune disease. 
  • IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp). 
  • Identification and characterization of a 100-kD ligand for CD6 on human thymic epithelial cells. 
  • Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. 
  • Identification and localization of a possible rhodopsin in the echinoderms Asterias forbesi (Asteroidea) and Ophioderma brevispinum (Ophiuroidea). 
  • Identification and visualization of multidimensional antigen-specific T-cell populations in polychromatic cytometry data. 
  • Identification of a common epitope between enterovirus 71 and human MED25 proteins which may explain virus-associated neurological disease. 
  • Identification of a synthetic peptide that mimics an HIV glycoprotein 120 envelope conformational determinant exposed following ligation of glycoprotein 120 by CD4. 
  • Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. 
  • Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes. 
  • Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. 
  • Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models. 
  • Identification of functional regions on the tail of Acanthamoeba myosin-II using recombinant fusion proteins. I. High resolution epitope mapping and characterization of monoclonal antibody binding sites. 
  • Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF. 
  • Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. 
  • Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand. 
  • Identifying key components of the PrPC-PrPSc replicative interface. 
  • Idiotypic analysis of a monoclonal anti-Sm antibody. 
  • Idiotypic analysis of a monoclonal anti-Sm antibody. II. Strain distribution of a common idiotypic determinant and its relationship to anti-Sm expression. 
  • Idiotypic cross-reaction between MRL monoclonal autoantibodies with different antigen specificity. 
  • Idiotypic determinants used in the analysis of antibody diversification and as regulatory targets. 
  • IgG antibodies from patients with bullous pemphigoid bind to fusion proteins encoded by BPAg1 cDNA. 
  • IgG antibodies from patients with bullous pemphigoid bind to localized epitopes on synthetic peptides encoded by bullous pemphigoid antigen cDNA. 
  • Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. 
  • Immunoaffinity purification of epitope-tagged human beta 2-adrenergic receptor to homogeneity. 
  • Immunoblot analyses of Candida albicans-associated antigens and antibodies in human sera. 
  • Immunodominance of Antibody Recognition of the HIV Envelope V2 Region in Ig-Humanized Mice. 
  • Immunofluorescent analysis of expression of the RNA tumor virus major glycoprotein, gp71, on surfaces of virus-producing murine and other mammalian species cell lines. 
  • Immunofluorescent analysis of expression of the RNA tumor virus major glycoprotein, gp71, on the surfaces of normal murine cells. 
  • Immunogenic determinants of a neuropathogenic murine leukemia virus. 
  • Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. 
  • Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins. 
  • Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state. 
  • Immunological correlates between the multiple hemocyanin subunits of Limulus polyphemus and Techypleus tridentatus. 
  • Immunological properties of avian oncornavirus polypeptides. 
  • Immunological studies of RNA polymerase II using antibodies to subunits of Drosophila and wheat germ enzyme. 
  • Immunoreactivity of apolipoprotein B-100 in oxidatively modified low density lipoprotein. 
  • Impact of HLA in mother and child on disease progression of pediatric human immunodeficiency virus type 1 infection. 
  • Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. 
  • Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. 
  • In vitro selection of RNA epitopes using autoimmune patient serum. 
  • In vitro selection of an RNA epitope immunologically cross-reactive with a peptide. 
  • In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. 
  • Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth. 
  • Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector. 
  • Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41. 
  • Induction of immune responses by schistosome granuloma macrophages. 
  • Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. 
  • Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. 
  • Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides. 
  • Infectious mononucleosis patients temporarily recognize a unique, cross-reactive epitope of Epstein-Barr virus nuclear antigen-1. 
  • Influence of CD4 T cells and the source of major histocompatibility complex class II-restricted peptides on cytotoxic T-cell priming by dendritic cells. 
  • Influence of assay conditions on ELISA determinations of anti-DNA antibodies. 
  • Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody. 
  • Influenza Antigen Engineering Focuses Immune Responses to a Subdominant but Broadly Protective Viral Epitope. 
  • Influenza Virus Vaccination Elicits Poorly Adapted B Cell Responses in Elderly Individuals. 
  • Inhibition of acanthamoeba actomyosin-II ATPase activity and mechanochemical function by specific monoclonal antibodies. 
  • Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages. 
  • Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. 
  • Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas. 
  • Interspecies determinants of Friend leukemia virus antigens involved in cytolysis of virus-pfoducing cells. 
  • Interspecies reactivity of type C and D retrovirus p 15E and p 15C proteins. 
  • Intracellular trafficking of angiotensin II and its AT1 and AT2 receptors: evidence for selective sorting of receptor and ligand. 
  • Intracerebral Expression of AAV-APOE4 Is Not Sufficient to Alter Tau Burden in Two Distinct Models of Tauopathy. 
  • Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. 
  • Involvement of multiple factors in the clonal deletion of self-reactive T cells. 
  • Isolation and characterization of the rat chromosomal gene for a polypeptide (pS1) antigenically related to statin. 
  • Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. 
  • Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. 
  • Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies. 
  • Isolation of monoclonal antibodies with predetermined conformational epitope specificity. 
  • Isolation of the nuclear gene encoding a subunit of the yeast mitochondrial RNA polymerase. 
  • L-selectin ligands expressed by human leukocytes are HECA-452 antibody-defined carbohydrate epitopes preferentially displayed by P-selectin glycoprotein ligand-1. 
  • LFA-1 binding site in ICAM-3 contains a conserved motif and non-contiguous amino acids. 
  • LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis. 
  • Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. 
  • Leukocyte adhesion molecule-1 (LAM-1, L-selectin) interacts with an inducible endothelial cell ligand to support leukocyte adhesion. 
  • Ligation of MHC class I and class II molecules can lead to heterologous desensitization of signal transduction pathways that regulate homotypic adhesion in human lymphocytes. 
  • Localization of cell wall polysaccharides in nonarticulated laticifers of Asclepias speciosa Torr. 
  • Localization of functionally important epitopes within the second C-type domain of coagulation factor V using recombinant chimeras. 
  • Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development. 
  • Longitudinal characterization of synovial fluid biomarkers in the canine meniscectomy model of osteoarthritis. 
  • Lupus autoantibodies recognize the product of an alternative open reading frame of SmB/B'. 
  • Lymphocytic lymphoma and systemic lupus erythematosus: their coexistence with antibody to the Sm antigen. 
  • MHC class I-peptide interactions and TCR recognition. 
  • Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses. 
  • Mammalian C-type oncorna viruses. Relationships between structural virus and cell surface antigens and their possible significance in immunological defense mechanisms. 
  • Mammalian C-type oncornaviruses: relationships between viral structural and cell-surface antigens and their possible significance in immunological defense mechanisms. 
  • Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. 
  • Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. 
  • Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk. 
  • Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants. 
  • Measles Virus Hemagglutinin epitopes immunogenic in natural infection and vaccination are targeted by broad or genotype-specific neutralizing monoclonal antibodies. 
  • Metabolism of pro-luteinizing hormone-releasing hormone in immortalized hypothalamic neurons. 
  • Microtubule-associated protein 1B (MAP1B) is present in glial cells phosphorylated different than in neurones. 
  • Microtubule-associated protein 2, a microtubule-associated protein from brain, is immunologically related to the alpha subunit of erythrocyte spectrin. 
  • Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. 
  • Mitosis is required for production of murine leukemia virus and structural proteins during de novo infection. 
  • Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants. 
  • Mixed lymphocyte responses in a four-generation C2 deficiency family. 
  • Modification of lupus-associated 60-kDa Ro protein with the lipid oxidation product 4-hydroxy-2-nonenal increases antigenicity and facilitates epitope spreading. 
  • Modified MHC restriction of donor-origin T cells in humans with severe combined immunodeficiency transplanted with haploidentical bone marrow stem cells. 
  • Modular complement assemblies for mitigating inflammatory conditions. 
  • Modulating adaptive immune responses to peptide self-assemblies. 
  • Molecular Docking and Molecular Dynamics (MD) Simulation of Human Anti-Complement Factor H (CFH) Antibody Ab42 and CFH Polypeptide. 
  • Molecular cloning of the cDNA for two major androgen-dependent secretory proteins of 18.5 kilodaltons synthesized by the rat epididymis. 
  • Molecular composition of an antigen-specific, Ly-1 T suppressor inducer factor. One molecule binds antigen and is I-J-; another is I-J+, does not bind antigen, and imparts an Igh-variable region-linked restriction. 
  • Molecular mapping of functional domains of the leukocyte receptor for endothelium, LAM-1. 
  • Molecular medicine: Defence against oxidative damage. 
  • Molecular studies of human renin structure and synthesis using monoclonal antibodies. 
  • Monoclonal antibodies demonstrate limited structural homology between myosin isozymes from Acanthamoeba. 
  • Monoclonal antibodies reactive with epitopes restricted to glial fibrillary acidic proteins of several species. 
  • Monoclonal antibodies that detect biochemical markers of arthritis in humans. 
  • Monoclonal antibodies to a human islet cell surface glycoprotein: 4F2 and LC7-2. 
  • Monoclonal antibodies to different epitopes on a prostate tumor-associated antigen. Implications for immunotherapy. 
  • Monoclonal antibodies to epitopes on different regions of the 200 000 dalton neurofilament protein. Probes for the geometry of the filament. 
  • Monoclonal antibodies to malignant human gliomas. 
  • Monoclonal antibody OKT3-induced T cell proliferation: differential role of HLA class II determinants expressed by T cells and monocytes. 
  • Monoclonal antibody recognizing a unique Rh-related specificity. 
  • Monolayer absorption of human cytotoxic T cells: evidence for clonality. 
  • Morphological, chemical, and antigenic organization of mammalian C-type viruses. 
  • Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). 
  • Multiepitope supramolecular peptide nanofibers eliciting coordinated humoral and cellular antitumor immune responses. 
  • Multiple assay characterization of murine monoclonal antimelanoma antibodies. 
  • Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity. 
  • Murine malignant cells synthesize a 19,000-dalton protein that is physicochemically and antigenically related to the immunosuppressive retroviral protein, P15E. 
  • Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft-versus-host disease. 
  • Murine monoclonal antibodies specific for conserved and non-conserved antigenic determinants of the human and murine Ku autoantigens. 
  • Mutations in a dominant Nef epitope of simian immunodeficiency virus diminish TCR:epitope peptide affinity but not epitope peptide:MHC class I binding. 
  • Myosins exist as homodimers of heavy chains: demonstration with specific antibody purified by nematode mutant myosin affinity chromatography. 
  • NMR-derived solution conformations of a hybrid synthetic peptide containing multiple epitopes of envelope protein gp120 from the RF strain of human immunodeficiency virus. 
  • Natural immunity to HIV and its possible relationship to vaccine strategies. 
  • Nature of the 3'-terminal sequences of the plus and minus strands of the S1 gene of reovirus serotypes 1, 2 and 3. 
  • Neo-epitope tissue transglutaminase autoantibodies as a biomarker of the gluten sensitive skin disease--dermatitis herpetiformis. 
  • Neonatal SHIV infection in rhesus macaques elicited heterologous HIV-1-neutralizing antibodies. 
  • Network interactions, 1982: audivi, legi, fugi. 
  • Neurological disorders with abnormalities of immunoglobulin metabolism. 
  • Neutralization epitopes of the HIV-1 primary isolate DH012. 
  • Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection. 
  • Neutralization of homologous and heterologous oncornaviruses by antisera against the p15(E) and gp71 polypeptides of Friend murine leukemia virus. 
  • Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. 
  • Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. 
  • Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers. 
  • Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. 
  • Newborn baboon serum anti-alpha galactosyl antibody levels and cytotoxicity to cultured pig kidney (PK15) cells. 
  • Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. 
  • Non-replicating mucosal and systemic vaccines: quantitative and qualitative differences in the Ag-specific CD8(+) T cell population in different tissues. 
  • Normal chicken cells (chf-) express a surface antigen which cross-reacts with determinants of the major envelope glycoprotein (gp85) of avian myeloblastosis virus. 
  • Oncogenic and immunogenic potential of cloned HIX virus in mice and cats. 
  • Oncogenic mutations in ras create HLA-A2.1 binding peptides but affect their extracellular antigen processing. 
  • Opposing effects of the D70 mutation and the shared epitope in HLA-DR4 on disease activity and certain disease phenotypes in rheumatoid arthritis. 
  • Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. 
  • Optimizing PLG nanoparticle-peptide delivery platforms for transplantation tolerance using an allogeneic skin transplant model. 
  • Outer membrane of avian myeloblastosis virus. 
  • Overlapping epitopes in human immunodeficiency virus type 1 gp120 presented by HLA A, B, and C molecules: effects of viral variation on cytotoxic T-lymphocyte recognition. 
  • PAS-C platelets contain less plasma protein, lower anti-A and anti-B titers, and decreased HLA antibody specificities compared to plasma platelets. 
  • Partial purification and characterization of a murine glioma-associated antigen defined by syngeneic rat monoclonal antibodies. 
  • Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection. 
  • Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection. 
  • Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading. 
  • Pathogenic Correlates of Simian Immunodeficiency Virus-Associated B Cell Dysfunction. 
  • Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. 
  • Peripheral blood mononuclear cells from patients with bullous pemphigoid have an increased frequency of response to synthetic peptides encoded by BPAG1. 
  • Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]. 
  • Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. 
  • Phenotypic characterization and ontogeny of mesodermal-derived and endocrine epithelial components of the human thymic microenvironment. 
  • Phospholipid vesicles interfere with the binding of antibody fragments to the light chain of factor VIII. 
  • Phosphorylation of microtubule-associated proteins by protein kinase CK2 in neuritogenesis. 
  • Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. 
  • Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers. 
  • Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. 
  • Polymorphism of human B-cell alloantigens: evidence for three loci within the HLA system. 
  • Polypeptides of avian RNA tumor viruses. IV. Components of the viral envelope. 
  • Polypeptides of endogenous avian C-type viruses: their detection in the plasma membrane of normal and infected cells. 
  • Polypeptides of mammalian oncornaviruses. I. Isolation and serological analysis polypeptides from murine and feline C-type viruses. 
  • Polypeptides of mammalian oncornaviruses. II Characterization of murine leukemia virus polypeptide (p 15) bearing interspecies reactivity. 
  • Polypeptides of mammalian oncornaviruses. III. Localization of p 15 and reactivity with natural antibody. 
  • Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes. 
  • Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1. 
  • Practical Considerations in the Design and Use of Immunologically Active Fibrillar Peptide Assemblies. 
  • Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope. 
  • Predominant envelope variable loop 2-specific and gp120-specific antibody-dependent cellular cytotoxicity antibody responses in acutely SIV-infected African green monkeys. 
  • Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial. 
  • Prevention of herpes keratitis by monoclonal antibodies specific for discontinuous and continuous epitopes on glycoprotein D. 
  • Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques. 
  • Production of monoclonal antibodies reacting with peripheral blood mononuclear cell surface differentiation antigens. 
  • Progress in vaccine development against SIV and HIV. 
  • Properties of mouse leukemia viruses. II. Isolation of viral components. 
  • Prostate and transitional cell carcinoma: radioimmunoassay of viral tumor-associated antigens. 
  • Prostate cancer cell proliferation in vitro is modulated by antibodies against glucose-regulated protein 78 isolated from patient serum. 
  • Pseudotyped viruses permit rapid detection of neutralizing antibodies in human and equine serum against Venezuelan equine encephalitis virus. 
  • Purification and serological characterization of the major envelope glycoprotein from AKR murine leukemia virus and its reactivity with autogenous immune sera from mice. 
  • Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. 
  • Quantitative determination that one of two potential RNA-binding domains of the A protein component of the U1 small nuclear ribonucleoprotein complex binds with high affinity to stem-loop II of U1 RNA. 
  • Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4. 
  • Quiescent phenotype of tumor-specific CD8+ T cells following immunization. 
  • RNA surfaces as functional mimetics of proteins. 
  • RNA-binding proteins to assess gene expression states of co-cultivated cells in response to tumor cells. 
  • Radioiodinated antibody targeting of the HER-2/neu oncoprotein. 
  • Randomization and selection of RNA to identify targets for RRM RNA-binding proteins and antibodies. 
  • Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1. 
  • Rat sulfite oxidase antibodies cross-react with two gene family-related proteins: albumin and vitamin D-binding protein. 
  • Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. 
  • Recognition by and in vitro induction of cytotoxic T lymphocytes against predicted epitopes of the immediate-early protein ICP27 of herpes simplex virus. 
  • Recognition of HLA-A2 mutant and variant target cells by an HLA-A2 allospecific human cytotoxic T lymphocyte line. 
  • Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. 
  • Region-specific anti-thyroid hormone receptor (TR) antibodies detect changes in TR structure due to ligand-binding and dimerization. 
  • Regulation of human interleukin-8 receptor A: identification of a phosphorylation site involved in modulating receptor functions. 
  • Regulation of the immune response. I. Regulatory cell equilibrium in the "virgin" state. 
  • Regulation of the tyrosine kinase-dependent adhesion pathway in human lymphocytes through CD45. 
  • Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection. 
  • Relationship of Inb antigen to other antigens on In(Lu)-related p80. 
  • Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein. 
  • Relationships between membrane antigens of human leukemic cells and oncogenic RNA virus structural components. 
  • Relative purity of thrombin-based hemostatic agents used in surgery. 
  • Release of amino-terminal fragments from amyloid precursor protein reporter and mutated derivatives in cultured cells. 
  • Renal allograft-infiltrating lymphocytes. A prospective analysis of in vitro growth characteristics and clinical relevance. 
  • Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains. 
  • Retinoblastoma protein monoclonal antibodies with novel characteristics. 
  • Ribosomal P autoantibodies are present before SLE onset and are directed against non-C-terminal peptides. 
  • Role of carbohydrate in determining the immunochemical properties of the major glycoprotein (gp71) of Friend murine leukemia virus. 
  • Role of germinal centers for the induction of broadly-reactive memory B cells. 
  • Role of phosphorylated MAPlB in neuritogenesis. 
  • Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor. 
  • Selective inhibition of natural killer activity by the monoclonal antibodies OKT10 and VEP10 at the single cell level. 
  • Selective recognition of DNA antigenic determinants by murine monoclonal anti-DNA antibodies. 
  • Selective small antigenic structures are capable of inducing widespread autoimmunity which closely mimics the humoral fine specificity of human SLE. 
  • Self-assembled peptide nanofibers raising durable antibody responses against a malaria epitope. 
  • Self-tolerance curtails the B cell repertoire to microbial epitopes. 
  • Sequencing of laminin B chain cDNAs reveals C-terminal regions of coiled-coil alpha-helix. 
  • Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity. 
  • Sequential expression of germ-layer specific molecules in the sea urchin embryo. 
  • Shift in S-layer protein expression responsible for antigenic variation in Campylobacter fetus. 
  • Short communication: HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding site epitopes. 
  • Sialic acid prevents loss of large von Willebrand factor multimers by protecting against amino-terminal proteolytic cleavage. 
  • Side-chain specificities and molecular modelling of peptide determinants for two anti-Sm B/B' autoantibodies. 
  • Signature for long-term vaccine-mediated control of a Simian and human immunodeficiency virus 89.6P challenge: stable low-breadth and low-frequency T-cell response capable of coproducing gamma interferon and interleukin-2. 
  • Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque. 
  • Single epitope mucosal vaccine delivered via immuno-stimulating complexes induces low level of immunity against simian-HIV. 
  • Soluble Envelope Glycoprotein Trimers from a CD4-Independent HIV-1 Elicit Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies in Guinea Pigs. 
  • Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAb lineage. 
  • Specificity and distribution of the determinants of the major glycoprotein (gp71) of murine oncornaviruses as detected by an in vitro cytotoxicity assay. 
  • Specificity and idiotype analysis of a monoclonal anti-DNA antibody. 
  • Specificity and immunochemical properties of antibodies to bacterial DNA in sera of normal human subjects and patients with systemic lupus erythematosus (SLE). 
  • Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. 
  • Specificity, cross-reactivity, and affinity of 125I-labeled antiglioma antibodies for monolayers of cultured glioma cells. 
  • Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers. 
  • Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein. 
  • Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions. 
  • Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates. 
  • Storage and mobilization of extracellular matrix proteins during sea urchin development. 
  • Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination. 
  • Streptokinase and human fibronectin share a common epitope: implications for regulation of fibrinolysis and rheumatoid arthritis. 
  • Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition. 
  • Structural analysis of HLA-A2 antigen from immunoselected mutant 8.6.1: further definition of an HLA-A2-specific serological determinant. 
  • Structural analysis of the functional sites of class I HLA antigens. 
  • Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens. 
  • Structural and functional features of the HIV envelope glycoprotein and considerations for vaccine development. 
  • Structural availability influences the capacity of autoantigenic epitopes to induce a widespread lupus-like autoimmune response. 
  • Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. 
  • Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies. 
  • Structural components of rna tumor viruses. 
  • Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection. 
  • Structurally Mapping Antigenic Epitopes of Adeno-associated Virus 9: Development of Antibody Escape Variants. 
  • Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. 
  • Structure and specific antigens of avian leukosis viruses. 
  • Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. 
  • Structure of the major peanut allergen Ara h 1 may protect IgE-binding epitopes from degradation. 
  • Structure-Guided Molecular Grafting of a Complex Broadly Neutralizing Viral Epitope. 
  • Structure-based Design of Cyclically Permuted HIV-1 gp120 Trimers That Elicit Neutralizing Antibodies. 
  • Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein. 
  • Superfibronectin, a multimeric form of fibronectin, increases HIV infection of primary CD4+ T lymphocytes. 
  • Supramolecular peptide vaccines: tuning adaptive immunity. 
  • Surface antigenic characteristics of human glial brain tumor cells. 
  • Surface antigens of human glioma cells shared with normal adult and fetal brain. 
  • Surface structure of human mucin using X-ray photoelectron spectroscopy. 
  • Synovial microenvironment-T cell interactions. Human T cells bind to fibroblast-like synovial cells in vitro. 
  • Synthetic Three-Component HIV-1 V3 Glycopeptide Immunogens Induce Glycan-Dependent Antibody Responses. 
  • Synthetic peptide in mineral oil adjuvant elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes in rhesus monkeys. 
  • Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys. 
  • Tabletized Supramolecular Assemblies for Sublingual Peptide Immunization. 
  • Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. 
  • Temporal correlation of antibody responses to different epitopes of the human La autoantigen. 
  • The 120-kDa soluble ectodomain of type XVII collagen is recognized by autoantibodies in patients with pemphigoid and linear IgA dermatosis. 
  • The B cell death function of obinutuzumab-HDEL produced in plant (Nicotiana benthamiana L.) is equivalent to obinutuzumab produced in CHO cells. 
  • The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen. 
  • The GTPase activating factor for transducin in rod photoreceptors is the complex between RGS9 and type 5 G protein beta subunit. 
  • The PDZ motif of the α1C subunit is not required for surface trafficking and adrenergic modulation of CaV1.2 channel in the heart. 
  • The U1 small nuclear ribonucleoprotein (snRNP) 70K protein is transported independently of U1 snRNP particles via a nuclear localization signal in the RNA-binding domain. 
  • The association of enhancement of renal allograft survival by donor-specific blood transfusion with host MHC-linked inhibition of IgG anti-donor class I alloantibody responses. 
  • The binding of anti-DNA antibodies to phosphorothioate oligonucleotides in a solid phase immunoassay. 
  • The canine MHC class Ia allele DLA-88*508:01 presents diverse self- and canine distemper virus-origin peptides of varying length that have a conserved binding motif. 
  • The desirable donor pig to eliminate all xenoreactive antigens. 
  • The extent of amino-terminal heterogeneity in rabbit fast skeletal muscle troponin T. 
  • The fine specificity of anti-La antibodies induced in mice by immunization with recombinant human La autoantigen. 
  • The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. 
  • The genetic determinant of adhesive function in type 1 fimbriae of Escherichia coli is distinct from the gene encoding the fimbrial subunit. 
  • The human thymic microenvironment. 
  • The human thymic microenvironment: cortical thymic epithelium is an antigenically distinct region of the thymic microenvironment. 
  • The immune response to staphylococcal nuclease: a probe of cellular and humoral antigen-specific receptors. 
  • The immunogenetics of the major histocompatibility chromosomal region in man. 
  • The influence of DNA size on the binding of anti-DNA antibodies in the solid and fluid phase. 
  • The mechanism of autoantibody production in an autoimmune MRL/lpr mouse. 
  • The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. 
  • The role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity. 
  • The role of antibodies in HIV vaccines. 
  • The role of antigen specificity in the binding of murine monoclonal anti-DNA antibodies to microparticles from apoptotic cells. 
  • The role of monogamous bivalency and Fc interactions in the binding of anti-DNA antibodies to DNA antigen. 
  • The role of the specificity-determining loop of the integrin beta subunit I-like domain in autonomous expression, association with the alpha subunit, and ligand binding. 
  • The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012. 
  • The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes. 
  • The three-dimensional structure of H-2Db at 2.4 A resolution: implications for antigen-determinant selection. 
  • The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation. 
  • Time course of degradation of cardiac troponin I in patients with acute ST-elevation myocardial infarction: the ASSENT-2 troponin substudy. 
  • Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes. 
  • Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. 
  • Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. 
  • Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors. 
  • Two classes of germline genes both derived from the V(H)1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII. 
  • Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. 
  • Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens. 
  • Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. 
  • Unique epitopes recognized by antibodies induced in Chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development. 
  • Urinary type II collagen neoepitope as an outcome measure for relapsing polychondritis. 
  • Use of anti-idiotypic antibodies to establish that monoclonal antibody 7H11D6 binds to the alpha 2-macroglobulin receptor recognition site. 
  • Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol. 
  • Using microcantilever deflection to detect HIV-1 envelope glycoprotein gp120. 
  • Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. 
  • Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. 
  • Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site. 
  • Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates. 
  • Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide. 
  • Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge. 
  • Variation in osteoarthritis biomarkers from activity not food consumption. 
  • Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses. 
  • Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. 
  • Virus-immune cytotoxic T cells recognize structural differences between serologically indistinguishable HLA-A2 molecules. 
  • Visualization of P-selectin glycoprotein ligand-1 as a highly extended molecule and mapping of protein epitopes for monoclonal antibodies. 
  • Wingless signaling generates pattern through two distinct mechanisms. 
  • Xenoreactivity of fetal and neonatal baboon intracellular antibody against the pig. 
  • ZIKV-Specific NS1 Epitopes as Serological Markers of Acute Zika Virus Infection. 
  • [Morphogenesis and structure of RNA tumor viruses. Electron microscopy studies on C-type viruses]. 
  • beta-Arrestin 2 expression determines the transcriptional response to lysophosphatidic acid stimulation in murine embryo fibroblasts. 
  • epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals. 
  • mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Bennett, Vann, George Barth Geller Distinguished Professor of Molecular Biology, Duke Cancer Institute
  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Cianciolo, George James, Associate Professor Emeritus of Pathology, Pathology
  • Ciofani, Maria, Associate Professor of Integrative Immunobiology, Cell Biology
  • Erickson, Harold Paul, James B. Duke Distinguished Professor Emeritus, Cell Biology
  • Ferrari, Guido, Professor in Surgery, Molecular Genetics and Microbiology
  • Kelsoe, Garnett H., James B. Duke Distinguished Professor of Immunology, Integrative Immunobiology
  • Krangel, Michael S., George Barth Geller Distinguished Professor of Immunology, Integrative Immunobiology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Pitt, Geoffrey Stuart, Adjunct Professor in the Department of Medicine, Medicine, Cardiology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Integrative Immunobiology